Reuters logo
BRIEF-Protalix Biotherapeutics announces positive interim results from phase II clinical trial of Alidornase Alfa
January 3, 2017 / 12:57 PM / 10 months ago

BRIEF-Protalix Biotherapeutics announces positive interim results from phase II clinical trial of Alidornase Alfa

Jan 3 (Reuters) - Protalix Biotherapeutics Inc :

* Protalix Biotherapeutics announces positive interim results from phase ii clinical trial of Alidornase Alfa (air dnase) for the treatment of cystic fibrosis

* Protalix Biotherapeutics Inc- “We are looking forward to reporting full results from study before end of Q1 of 2017.”

* Protalix Biotherapeutics Inc- no serious adverse events were reported in interim results from phase II clinical trial of Alidornase Alfa Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below